# Performance of a Valved Holding Chamber with Tracheostomy Adapter: **Aerosol Delivery from Soft Mist Inhalers**

### RATIONALE

- Patients with asthma or obstructive airways disease who have a tracheostomy tube (TT) or tracheal stoma have difficulty using Metered Dose Inhalers (MDIs) because of a failure to achieve a good seal between the TT and delivery device.
- We report the outcome of a study that investigated aerosol delivery from Soft Mist Inhalers (SMI) to a breathing tracheostomy model via a Valved Holding Chamber (VHC) with tracheostomy adapter

### MATERIALS AND METHODS



AeroTrach Plus\* VHC Trudell Medical International





MD-027A-0419. \* trade-marks and registered trade-marks of Trudell Medical International. † trade-marks and registered trade-marks of their respective companies. Copyright © Trudell Medical International 2019

### M. Nagel<sup>1</sup>, R. Ali<sup>1</sup>, C. Doyle<sup>1</sup>, D.P. Coppolo<sup>2</sup>, J. Suggett<sup>1</sup>

<sup>1</sup> Trudell Medical International, London, Canada. <sup>2</sup> Monaghan Medical Corporation, Plattsburgh, NY, USA.



- AeroTrach Plus\* VHCs were evaluated for active pharmaceutical ingredients (API) from the 3 different SMI formulations.
  - n = 5 replicates/device
- The tracheostomy adapter of the VHC was attached to the 15 mm adapter of the adult TT (6 mm I.D., 70 mm long Portex)
  - The cuff of the tube was used to seal the exit to a bacterial viral filter.
- The filter was in turn connected to a breathing simulator (ASL 5000, IngMar Medical) which was operated to simulate tidal breathing
  - Tidal Volume = 500 mL
  - 13 breaths per minute (bpm)
  - Inspiratory : Expiratory ratio of 1:2
- The SMI was placed in the adapter of the VHC and following actuation of the SMI, 5 breathing cycles were undertaken, following which the test apparatus was disassembled and the mass of API deposited on the filter assayed by HPLC.



Trudell Medical International\*

### RESULTS

Soft Mist Inhaler Formulation

Spiriva<sup>†</sup> Respimat<sup>†</sup>

Inspiolto<sup>†</sup> Respimat<sup>†</sup>

Combivent<sup>+</sup> Respimat<sup>+</sup>

## CONCLUSIONS

- *in vitro* findings.

Active Ingredient (label claim, μg)	Dose Delivered to Distal End of Tracheostomy Tube (µg)
tiotropium bromide monohydrate (2.5µg)	1.3 ± 0.2
olodaterol hydrochloride (2.5µg)	1.1 ± 0.2
tiotropium bromide monohydrate (2.5µg)	1.1 ± 0.2
salbutamol (100µg)	27.2 ± 5.3
ipratropium bromide (20µg)	$4.9 \pm 1.0$

• Based on these laboratory data, the VHC with tracheostomy adaptor appears to provide a reliable means of delivering SMI aerosols to patients with a tracheostomy tube or tracheal stoma.

• Further research is required to determine the clinical relevance of these



### Excellence by Design